Crescent BioPharma (CBIO) CFO Richard Scalzo Sells 568 Shares

What Happened CFO Richard William Scalzo reported an open-market sale of 568 shares of Crescent BioPharma (CBIO) on September 16, 2026, for a weighted average price of $17.90, totaling approximately $10,167. The sale is a disposition (S) and was made to satisfy tax withholding obligations in connection with settlement of restricted stock units (RSUs).

Key Details

• Transaction date: 2026-09-16 (Filed: 2026-09-18) — filing appears timely.
• Quantity and price: 568 shares sold; weighted average price $17.90; individual trade prices ranged $17.10–$19.17 (per footnote).
• Total proceeds: ~$10,167.
• Reason / footnotes: Per footnote, the shares were automatically sold to cover tax withholding for RSUs granted Dec 15, 2025; sales were effected pursuant to a Rule 10b5-1 plan adopted Feb 25, 2026 (F1).
• Price detail: Footnote notes weighted average and availability of per-trade breakdown upon request (F2).
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context This sale was executed under a pre-established 10b5-1 instruction solely to cover tax withholding on vested RSUs — a routine administrative transaction that does not necessarily indicate a change in the officer’s view of the company. Retail investors should view such tax-related disposals differently from discretionary sales intended to realize investment gains.